A study of 468 healthy newborns shows that infants given the probiotic
Lactobacillus reuteri Protectis cried less than half as long as infants given a
placebo. The infants given Lactobacillus reuteri Protectis also had
significantly fewer daily regurgitations and were less constipated compared to
infants in the placebo group. As a result, the use of Lactobacillus
reuteri Protectis proved to be cost saving for both parents and the community.
“This is the first study proving prophylactic use of a specific strain (L.
reuteri Protectis) in a condition like functional gastrointestinal disorders
(colic, regurgitation and constipation). Moreover this is also the first
evaluation of the cost/benefit for a probiotic therapy in infants and it shows
that L. reuteri Protectis is valuable for the family and for the society,” says
Doctor Flavia Indrio, MD, Department of Paediatrics, University of Bari, Italy.
Less crying, less constipation, less regurgitation…
Intervention started the first days of life. After one month’s use of
Lactobacillus reuteri Protectis drops the infants cried less than half as long
per day as the infants given placebo, 45 minutes compared to 96 minutes. The
significant difference between the groups persisted to the end of the three
The infants in the Lactobacillus reuteri Protectis group also had a better gut
motility, leading to significantly more daily evacuations and less regurgitation
compared to infants in the placebo group.
…means less costs for family and community
Not only could colic, regurgitation and constipation cause the baby pain. These
conditions often lead to numerous visits to the paediatrician and also
hospitalisation and use of drugs, as well as anxiety and loss of working days
for the parents. Only by calculating the direct costs, the investigators
concluded that use of Lactobacillus reuteri Protectis saved each family 88 euro.
In addition to this the community saved 104 euro per child.
“This study is ground breaking as it shows that BioGaia’s product should be
given to all babies from birth. Not only does it reduce suffering in babies and
parents, but it also saves the families and the society costs. This study will
be immensely important for the further development of BioGaia’s baby segment,”
says Peter Rothschild, President BioGaia.
The study was published in the highly regarded medical journal JAMA Pediatrics
on 13 January
2014 (http://archpedi.jamanetwork.com/article.aspx?articleid=1812293). More
information on colic, constipation,
df) and an interview with Dr Indrio (http://youtu.be/LxX4EesCXXc) is found
through attached links.
Latest press releases from BioGaia
2013-12-05 One of the world’s most widespread infections – BioGaia’s Gastrus
2013-11-15 BioGaia signs exclusive agreement for drops and tablets in Brazil
2013-11-12 BioGaia invests in development of a drug against NEC
BioGaia has published this information in accordance with the Swedish Securities
Market Act. The information was issued for publication on 14 January 2014, 08:00
For additional information please contact
Peter Rothschild, Chief Executive Officer, BioGaia: 46 8 555 293 00
BioGaia is a healthcare company that develops, markets and sells probiotic
products with documented health benefits. The products are primarily based on
the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health
-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted
on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com
GlobeNewswire, a Nasdaq company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.